Firstly, previous studies reported that regrafenib targets multiple tumor pathways involved in biliary tumorigenesis, including EGFR, RAS, RAF, VEGFR, FGFR, and PDGFR signaling pathways (7–10). Here, KDR is linked to neoplasm.